Abstract
Objectives: The present study’s design investigated the lipid parameters level and atherogenic index in atherosclerosis and cardiovascular disease risk development in chronic obstructive pulmonary disease patients.
Methods: The study consists of 108 clinically diagnosed and confirmed spirometry-stable chronic obstructive pulmonary disease (COPD) patients (Mild, Moderate, and Severe), and the controls were 36 healthy individuals of the same age and sex. Blood samples were collected and the lipid profile was done. The atherogenic index of all COPD patients was calculated using the values of lipid parameters.
Results: The observation revealed that as compared to the control group, total cholesterol, triglycerides, low-density lipoproteins (LDL), and very LDLs were significantly (p<0.001) raised in all the COPD sub-groups, and high-density lipoproteins levels showed significantly (p<0.001) decreasing levels in all COPD groups as compared to controls. The COPD sub-group has a higher atherogenic risk (p<0.001) than controls.
Conclusion: In COPD patients with dyslipidemia, there is an increased atherogenic risk, which predicts future cardiovascular risk.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference35 articles.
1. Jindal SK, Gupta D, Aggarwal AN. Guidelines for the management of chronic obstructive pulmonary disease in India: A guide for physician (2003). Indian J Chest Dis Allied Sci 2004;46:137-93.
2. Van Iwaarden F, Welmers B, Verhoef J, Haagsman HP, Van Golde LM. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990;12:91-8.
3. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007;370:765-73.
4. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-51.
5. Maclay JD, MacNee W. Cardiovascular disease in COPD: Mechanisms. Chest 2013;143:798-807.